Aigen Investment Management LP Increases Holdings in Enovis Co. (NYSE:ENOV)

Aigen Investment Management LP raised its stake in Enovis Co. (NYSE:ENOV) by 5.1% during the third quarter, HoldingsChannel reports. The fund owned 8,859 shares of the company’s stock after buying an additional 430 shares during the period. Aigen Investment Management LP’s holdings in Enovis were worth $381,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ENOV. River Road Asset Management LLC bought a new stake in shares of Enovis during the third quarter valued at approximately $51,341,000. American Century Companies Inc. grew its holdings in shares of Enovis by 78.6% in the second quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock worth $68,337,000 after acquiring an additional 665,208 shares during the period. Magnetar Financial LLC increased its position in shares of Enovis by 66.7% during the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock valued at $49,937,000 after purchasing an additional 442,051 shares during the last quarter. Diamond Hill Capital Management Inc. increased its holdings in Enovis by 14.5% during the second quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock valued at $125,929,000 after buying an additional 352,116 shares during the last quarter. Finally, Boston Partners increased its stake in shares of Enovis by 206.5% in the 1st quarter. Boston Partners now owns 295,969 shares of the company’s stock worth $18,455,000 after purchasing an additional 199,411 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Stock Down 1.9 %

Shares of NYSE ENOV opened at $45.59 on Friday. The stock has a 50 day moving average price of $42.33 and a 200 day moving average price of $45.33. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of -20.81 and a beta of 1.91. Enovis Co. has a 52-week low of $38.27 and a 52-week high of $65.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. The business had revenue of $505.22 million for the quarter, compared to the consensus estimate of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business’s revenue was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.56 EPS. Sell-side analysts expect that Enovis Co. will post 2.79 earnings per share for the current year.

Analysts Set New Price Targets

ENOV has been the subject of a number of analyst reports. JMP Securities started coverage on shares of Enovis in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC restated a “buy” rating and set a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. Finally, Evercore ISI lowered their price target on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $67.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.